Neuroleptic malignant syndrome responsive to carbidopa/levodopa: support for a dopaminergic pathogenesis.
A 31-year-old man with psychosis and neuroleptic-induced tardive dystonia developed neuroleptic malignant syndrome (NMS) while taking haloperidol. Muscle rigidity responded to dantrolene, but hyperthermia did not abate until therapy with carbidopa/levodopa was initiated, after which temperature varied in direct relationship to subsequent levodopa administration. This supports the role for central dopaminergic mechanisms in the pathogenesis of NMS.
D000328:Adult; D002230:Carbidopa / Q000627:therapeutic use*; D004338:Drug Combinations; D006220:Haloperidol / Q000009:adverse effects; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000188:drug therapy*; D011618:Psychotic Disorders / Q000188:drug therapy
D004338:Drug Combinations; D007980:Levodopa; D006220:Haloperidol; D002230:Carbidopa